The modern age of drug discovery, which had been slowly gathering momentum during the
early part of the twentieth century, exploded into life in the 1940s with the isolation of …

Metal-based drugs are privileged motifs that act as primary pharmacophores in bioactive
compounds for various diseases, including tuberculosis (TB). This potentially life-threatening …

We recently reported the initiation of a Phase I clinical trial with AB680, a potent human
CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973). We …

Mycobacterium tuberculosis InhA (Mt InhA) is an attractive enzyme to drug discovery efforts
due to its validation as an effective biological target for tuberculosis therapy. In this work, two …

The modern approach to the development of new chemical entities against complex
diseases, especially the neglected endemic diseases such as tuberculosis and malaria, is …

The bacterial type II fatty acid biosynthesis (FASII) pathway is an essential but unexploited
target for drug discovery. In this review we summarize SAR studies on inhibitors of InhA, the …

Tuberculosis (TB) accounted for 1.5 million deaths in 2014, and new classes of anti-TB
drugs are required. We report a class of functionalized 1, 8-disubstituted cyclam derivatives …

The synthesis, characterization and the anti-Mycobacterium tuberculosis (MTB) activities of
three ruthenium complexes containing the 2-pyridinecarboxylic acid anion (picolinate), with …

Mycobacterium tuberculosis is the etiologic agent of tuberculosis. The demand for new
chemotherapeutics with unique mechanisms of action to treat (multi) resistant strains is an …

Despite the resistance developed by the Mycobacterium tuberculosis (MTb) strains,
isoniazid (INH) has been recognized as one of the best drug for treatment of Tuberculosis …